Asieris(SH:688176)2025-02-27 09:25Financial Performance - The company reported total operating revenue of RMB 20,162.49 million for the reporting period, a significant increase of 1,366.01% compared to RMB 1,375.33 million in the same period last year[2]. - The net loss attributable to the parent company was RMB -38,767.89 million, a decrease from RMB -40,043.46 million year-on-year, indicating improved financial performance[5]. - The total assets at the end of the reporting period were RMB 222,399.91 million, representing a year-on-year decrease of 15.51%[5]. - The equity attributable to the parent company decreased by 17.75% year-on-year, amounting to RMB 196,398.72 million[5]. - The company achieved a basic earnings per share of RMB -0.69, slightly improved from RMB -0.70 in the previous year[2]. Product Development and Commercialization - The company has made significant progress in the commercialization of its core products, with sales from Pazopanib tablets and Neralitinib tablets contributing to revenue growth[5]. - The company is actively pursuing clinical trials and product development, with APL-1706 receiving approval from the NMPA seven months ahead of schedule[6]. - The company is focusing on developing new products such as AT-014 and AT-020, which show promising efficacy and safety profiles compared to existing treatments[7]. Operational Strategy - The company aims to enhance cost control and resource allocation to improve operational efficiency and reduce losses[9]. - Investors are advised to be cautious as the financial data presented is preliminary and unaudited, with potential discrepancies in the final annual report[10].